insights_auto
Why is LXRX up 2.20%?
Dive Deeperchevron_right
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$1.86
arrow_upward
+2.20%(+0.040) 1D
$1.85
arrow_downward
-0.52% (-0.0097)bedtimeAfter hours
Closed: Nov 10, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LXRX...
Open
$1.80
High
$1.97
Low
$1.80
Mkt. cap
828.14M
Avg. vol.
2.13M
Volume
3.41M
52-wk high
$2.68
52-wk low
$1.10
EPS
-$0.15
Beta
1.46
Shares outstanding
445.24M
No. of employees
81
Open
$1.80
High
$1.97
Low
$1.80
Mkt. cap
828.14M
Avg. vol.
2.13M
Volume
3.41M
52-wk high
$2.68
52-wk low
$1.10
EPS
-$0.15
Beta
1.46
Shares outstanding
445.24M
No. of employees
81
News stories
From web sources and news partners
GuruFocus
·
1 day ago
Lexicon Pharmaceuticals (LXRX) CEO Michael Exton Buys 30,064 Sha
Investing.com
·
1 day ago
Lexicon Pharmaceuticals CEO Michael Exton buys $49,999 in shares
Quantisnow
·
1 day ago
Lexicon Pharmaceuticals (LXRX) CEO Exton bought 30,064 shares for $50K at $1.66
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc
CEOLonnel Coats
Employees81
Founded1995
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitelexpharma.com